tradingkey.logo

Nexalin Technology Inc

NXL

0.979USD

-0.010-1.04%
Market hours ETQuotes delayed by 15 min
13.04MMarket Cap
LossP/E TTM

Nexalin Technology Inc

0.979

-0.010-1.04%
More Details of Nexalin Technology Inc Company
Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
Company Info
Ticker SymbolNXL
Company nameNexalin Technology Inc
IPO dateSep 16, 2022
CEOMr. Mark White
Number of employees6
Security typeOrdinary Share
Fiscal year-endSep 16
Address1776 Yorktown
CityHOUSTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code77056
Phone18322600222
Websitehttps://nexalin.com
Ticker SymbolNXL
IPO dateSep 16, 2022
CEOMr. Mark White
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
149.29K
--
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+25.00%
Dr. Ben V. Hu, M.D.
Dr. Ben V. Hu, M.D.
Independent Director
Independent Director
--
--
Mr. Justin Van Fleet
Mr. Justin Van Fleet
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Marilyn Elson
Ms. Marilyn Elson
Controller
Controller
1.54M
--
Mr. Mark White
Mr. Mark White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
309.13K
--
Dr. David Owens, M.D.
Dr. David Owens, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
149.29K
--
Mr. Alan Kazden
Mr. Alan Kazden
Independent Director
Independent Director
83.13K
--
Ms. Leslie Bernhard
Ms. Leslie Bernhard
Independent Chairman of the Board
Independent Chairman of the Board
49.84K
--
Ms. Carolyn Hamby Shelton
Ms. Carolyn Hamby Shelton
Senior Vice President - Quality, Regulatory and Clinical Affairs
Senior Vice President - Quality, Regulatory and Clinical Affairs
30.00K
+25.00%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Equipment
19.81K
48.30%
Licensing Fee
17.31K
42.21%
Other
3.89K
9.48%
Device Sales
0.00
0.00%
By RegionUSD
Name
Revenue
Proportion
International Sales
20.57K
50.16%
U.S. Sales
20.44K
49.84%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Equipment
19.81K
48.30%
Licensing Fee
17.31K
42.21%
Other
3.89K
9.48%
Device Sales
0.00
0.00%
Shareholding Stats
Updated: Thu, Jul 31
Updated: Thu, Jul 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Elson (Marilyn)
8.81%
Hu (Benjamin)
1.96%
White (Mark)
1.77%
The Vanguard Group, Inc.
0.92%
Owens (David)
0.86%
Other
85.68%
Shareholders
Shareholders
Proportion
Elson (Marilyn)
8.81%
Hu (Benjamin)
1.96%
White (Mark)
1.77%
The Vanguard Group, Inc.
0.92%
Owens (David)
0.86%
Other
85.68%
Shareholder Types
Shareholders
Proportion
Individual Investor
14.34%
Investment Advisor
1.22%
Investment Advisor/Hedge Fund
0.98%
Hedge Fund
0.07%
Other
83.39%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
41
2.88M
16.53%
-345.33K
2025Q1
40
2.89M
20.99%
-330.73K
2024Q4
39
2.84M
22.05%
+425.03K
2024Q3
30
2.89M
23.47%
+756.88K
2024Q2
27
1.82M
24.31%
-214.81K
2024Q1
20
1.77M
23.82%
-386.75K
2023Q4
19
1.75M
24.04%
-404.23K
2023Q3
19
1.79M
24.48%
+126.81K
2023Q2
18
1.72M
23.56%
+25.67K
2023Q1
20
1.79M
24.55%
+114.75K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Elson (Marilyn)
1.54M
8.81%
--
--
Jun 04, 2025
Hu (Benjamin)
340.64K
1.96%
--
--
Jun 04, 2025
White (Mark)
309.13K
1.77%
--
--
Jun 04, 2025
The Vanguard Group, Inc.
159.88K
0.92%
+34.42K
+27.43%
Mar 31, 2025
Owens (David)
149.29K
0.86%
--
--
Jun 04, 2025
Geode Capital Management, L.L.C.
114.07K
0.65%
+6.83K
+6.37%
Mar 31, 2025
Kazden (Alan)
83.13K
0.48%
--
--
Jun 04, 2025
Bernhard (Leslie)
49.84K
0.29%
--
--
Jun 04, 2025
State Street Global Advisors (US)
32.30K
0.19%
--
--
Mar 31, 2025
Shelton (Carolyn Hamby)
30.00K
0.17%
+6.00K
+25.00%
Jun 04, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI